{"meshTagsMajor":["Mutation"],"meshTags":["Adenocarcinoma","Aged","Antineoplastic Combined Chemotherapy Protocols","Disease Progression","Drug Administration Schedule","Female","Humans","Lung Neoplasms","Molecular Targeted Therapy","Mutation","Oncogene Proteins, Fusion","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Quinazolines","Receptor, Epidermal Growth Factor","Treatment Outcome"],"meshMinor":["Adenocarcinoma","Aged","Antineoplastic Combined Chemotherapy Protocols","Disease Progression","Drug Administration Schedule","Female","Humans","Lung Neoplasms","Molecular Targeted Therapy","Oncogene Proteins, Fusion","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Quinazolines","Receptor, Epidermal Growth Factor","Treatment Outcome"],"genes":["epidermal growth factor receptor","EML4","ALK"],"publicationTypes":["Case Reports","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"title":"Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.","pubmedId":"24419120"}